# US 5,703,077 A · Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,703,077 A - Document ID: US5703077A - Status: Granted - Kind: A - Application number: 08/693,745 - Filed: 1996-08-07 - Granted: 1997-12-30 - Earliest claimed: 1993-10-13 - Assignees: Allergan, Inc. - Inventors: James A. Burke; Michael E. Garst; Larry A. Wheeler - Web page: https://patentgrep.com/patent/US5703077A ## CPC - A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine - A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) - A61P 1/12: Antidiarrhoeals - A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents - A61P 7/10: Antioedematous agents; Diuretics - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61P 9/12: Antihypertensives - A61P 11/02: Nasal agents, e.g. decongestants - A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers - A61P 13/12: of the kidneys - A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives - A61P 23/00: Anaesthetics - A61P 23/02: Local anaesthetics - A61P 25/00: Drugs for disorders of the nervous system - A61P 25/02: for peripheral neuropathies - A61P 25/04: Centrally acting analgesics, e.g. opioids - A61P 27/16: Otologicals - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms wherein the desired therapeutic effect is an increase in renal fluid flow. ## Claims ### Claim 1 A method of treating a mammal comprising administering to a mammal an effective amount to provide a desired therapeutic effect in said mammal of a compound selected from the group consisting of those having the formula ##STR4## and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.2 each is selected from the group consisting of H, alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms provided that R.sub.1 and R.sub.2 are not both H, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 each is located in one of the remaining 5-, 6- 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms, said desired therapeutic effect being an increase in renal fluid flow. ### Claim 2 (depends on 1) The method of claim 1 wherein the 2-imidazolin-2-ylamino group is in the 6- position of the quinoxaline nucleus, R.sub.3 is in the 5- position of the quinoxaline nucleus and is selected from the group consisting of Cl, Br and alkyl radicals containing 1 to 3 atoms, and R.sub.4 and R.sub.5 are both H. ### Claim 3 (depends on 2) The method of claim 2 wherein R.sub.2 is a methyl radical. ### Claim 4 (depends on 3) The method of claim 3 wherein R.sub.3 is Br. ### Claim 5 (depends on 2) The method of claim 2 wherein R.sub.3 is Br. ### Claim 6 (depends on 1) The method of claim 1 wherein R.sub.2 is a methyl radical. ### Claim 7 (depends on 1) The method of claim 1 wherein R.sub.1 is H and R.sub.2 is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms. ### Claim 8 (depends on 1) The method of claim 1 wherein said formula is: ##STR5## ### Claim 9 (depends on 1) The method of claim 1 wherein R.sub.3 is in the 5- position of the quinoxaline nucleus and is selected from the group consisting of H and alkyl radicals containing 1 to 3 carbon atoms. ### Claim 10 (depends on 9) The method of claim 9 wherein the 2-imidazolin-2-ylamino group is in the 6- position of the quinoxaline nucleus, and R.sub.4 and R.sub.5 are both H. ### Claim 11 (depends on 10) The method of claim 10 wherein R.sub.3 is selected from the group consisting of H and methyl radical. ### Claim 12 (depends on 9) The method of claim 9 wherein R.sub.3 is selected from the group consisting of H and methyl radical. ### Claim 13 A method of treating a mammal comprising administering to a mammal an effective amount to provide a desired therapeutic effect in said mammal of a compound selected from the group consisting of those having the formula ##STR6## and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.2 each is independently selected from the group consisting of H, alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 each is located in one of the remaining 5-, 6- 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, H and alkyl radicals containing 1 to 3 carbon atoms, said desired therapeutic effect being an increase in renal fluid flow. ### Claim 14 (depends on 13) The method of claim 13 wherein both R.sub.1 and R.sub.2 are H. ### Claim 15 (depends on 13) The method of claim 13 wherein R.sub.3 is selected from the group consisting of H and methyl radical. ### Claim 16 (depends on 13) The method of claim 13 wherein said formula is: ##STR7## ### Claim 17 (depends on 13) The method of claim 13 wherein said formula is: ##STR8## ### Claim 18 (depends on 13) The method of claim 13 wherein the 2-imidazolin-2-ylamino group is in the 6- position of the quinoxaline nucleus, R.sub.3 is in the 5- position of the quinoxaline nucleus and is selected from the group consisting of Cl and alkyl radicals containing 1 to 3 atoms, and R.sub.4 and R.sub.5 are both H. ### Claim 19 (depends on 13) The method of claim 13 wherein R.sub.3 is in the 5- position of the quinoxaline nucleus and is selected from the group consisting of H and alkyl radicals containing 1 to 3 carbon atoms, the 2-imidazolin-2-ylamino group is in the 6- position of the quinoxaline nucleus, R.sub.1 and R.sub.2 are both H, and R.sub.4 and R.sub.5 are both H.